Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Crocs Inc is a footwear & accessories business based in the US. Crocs shares (CROX) are listed on the NASDAQ and all prices are listed in US Dollars. Crocs employs 4,600 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$156.30|
|52-week range||$41.29 - $163.18|
|50-day moving average||$145.05|
|200-day moving average||$112.04|
|Wall St. target price||$178.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$9.87|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||0.72%|
|1 month (2021-08-25)||8.69%|
|3 months (2021-06-25)||36.61%|
|6 months (2021-03-25)||101.05%|
|1 year (2020-09-25)||266.73%|
|2 years (2019-09-25)||458.41%|
|3 years (2018-09-25)||633.46%|
|5 years (2016-09-23)||1,740.99%|
Valuing Crocs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Crocs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Crocs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Crocs shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Crocs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $531.4 million.
The EBITDA is a measure of a Crocs's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.9 billion|
|Operating margin TTM||26.76%|
|Gross profit TTM||$749.9 million|
|Return on assets TTM||27.2%|
|Return on equity TTM||190.44%|
|Market capitalisation||$9.8 billion|
TTM: trailing 12 months
There are currently 2.7 million Crocs shares held short by investors – that's known as Crocs's "short interest". This figure is 1.6% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting Crocs shares can be evaluated.
Crocs's "short interest ratio" (SIR) is the quantity of Crocs shares currently shorted divided by the average quantity of Crocs shares traded daily (recently around 844836). Crocs's SIR currently stands at 3.25. In other words for every 100,000 Crocs shares traded daily on the market, roughly 3250 shares are currently held short.
However Crocs's short interest can also be evaluated against the total number of Crocs shares, or, against the total number of tradable Crocs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Crocs's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Crocs shares in existence, roughly 40 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Crocs shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Crocs.
Find out more about how you can short Crocs stock.
We're not expecting Crocs to pay a dividend over the next 12 months.
Crocs's shares were split on a 2:1 basis on 14 June 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Crocs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Crocs shares which in turn could have impacted Crocs's share price.
Over the last 12 months, Crocs's shares have ranged in value from as little as $41.29 up to $163.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crocs's is 1.8379. This would suggest that Crocs's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crocs, Inc. , together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children. It offers various footwear products, including sandals, wedges, flips, slides clogs, charms, and shoes under the Crocs brand name. The company sells its products in approximately 80 countries through wholesalers, retail stores, e-commerce sites, and third-party marketplaces. As of December 31, 2020, it had 186 outlet stores, 100 retail stores, 65 store-in-stores, and 13 company-operated e-commerce sites. The company serves in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Crocs, Inc.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.